Overview

This study is a prospective, randomized pilot study. To verify an efficacy and safety of the Intratympanic drug delivery vehicle, patients who have not responded to the existing standard treatment will be enrolled. Hearing test, endoscopy of tympanic membrane and CT scans will be conducted after intratympanic treatment for evaluation.

Eligibility

Inclusion Criteria:

• Sudden hearing loss, ototoxic hearing loss, noise-induced hearing loss, meniere's disease patients with 25dB HL in pure tone audiometry
• Patients whose hearing has not been restored after standard treatment
• Patients do not participate in clinical trials within 6 months

Exclusion Criteria:

• Patients with retrocochlear lesion
• Patients with history of hypersensitivity to the ingredients of this drug
• Patients with end-stage renal disease, end-stage liver disease, cardiovascular surgery, progressive brain tumor, progressive palsy and progressive stroke, etc. severe brain disease or cancer.